Estradiol Patch Shortage Tracker: What’s Backordered in 2026

At the October 3, 2026 source check, ASHP’s estradiol-patch bulletin listed17 affected and 29available NDC/package entries. FDA’s drug-shortage data, updated October 2, contained no matching Current estradiol record. FDA separately acknowledged access problems in its September 3 update and said manufacturers were expanding supply. These sources do not show stock at a particular pharmacy.

Two quick definitions, because they matter here. A “back order” means a manufacturer can’t currently ship a product. “Allocation” means a manufacturer is rationing a product to existing contracted customers. Neither appeared as a Current estradiol record in the targeted FDA query. Here is the source-specific snapshot.

Three sources, three vantage points: ASHP lists affected presentations, including once-weekly and twice-weekly products, while the targeted FDA query found no matching Current estradiol record. The FDA weighs national supply reported by manufacturers; ASHP catalogs product-level problems; Truveta measures what actually left the pharmacy counter. They can all be right at once — and reporting from The New York Times(February 2026) and NPR (March 2026) has documented patients struggling to fill specific brands and strengths even as the FDA’s list stayed clear.

What this does notshow is your local pharmacy’s shelf. A product we list as “available” may be out of stock at your store this week, and a product on the affected list may be sitting behind the counter across town. This is a national source tracker, not a live inventory checker — and it is educational information, not medical advice. If your patch is unavailable, your pharmacist and prescriber are the right people to sort out a substitute.

Is your patch actually unavailable?

See our practical step-by-step guide to refills, pharmacy substitutions, switching forms, and when an online clinician can help.

What to do if you can’t refill your estradiol patch →

Need a clinician who can review a different form or send a prescription to your own pharmacy? Our free, private Find My HRT Path tool routes by payment method, state, and safety history in about 90 seconds. It does not check pharmacy stock or give dosing advice.

We assembled this from primary sources and did the counting ourselves.We read the FDA’s public shortage database and the agency’s on-the-record statements, pulled ASHP’s “Estradiol Transdermal System” bulletin directly, and counted every product it lists as affected and as available. For demand, we used Truveta’s published real-world analysis rather than secondhand summaries.

Our counting rule is simple and reproducible: each ASHP line item in “Products Affected” or “Available Products” counts as one NDC/package entry. These are not counts of prescriptions or local inventory. We do not treat forum posts, pharmacy anecdotes, or clinic marketing pages as shortage evidence — those describe how people experience the problem, not what’s true. Every figure below carries a source and a date. For a plain-language guide to the terminology used here, see our Menopause & HRT Glossary.

• FDA position:a targeted October 3 query of FDA drug-shortage data, updated October 2, found no matching Current estradiol record. FDA’s September 3 supply statement separately acknowledges access difficulties and work to expand output. Check the live FDA Drug Shortages database for the current status.
• ASHP product status: ASHP Drug Shortage Bulletin, "Estradiol Transdermal System" (id=1206), updated August 12, 2026; checked October 3, 2026. Counts are NDC/package entries from the supplied snapshot. It lists 17 affected and 29 available NDC/package entries under the one-line-item counting rule.
• Demand data: Truveta Research, published April 9, 2026, reflecting data as of March 30, 2026.

ASHP’s August 12 bulletin, checked October 3, lists 17 affected NDC/package entries. The affected list includes both once-weekly and twice-weekly products, so schedule alone is not a reliable shortcut for finding supply.

Twice-weekly patches (applied two times a week, sold in 8-count boxes) include Dotti, Lyllana, Vivelle-Dot, and Minivelle. Once-weekly patches (applied once a week, sold in 4-count boxes) include Climara. Some manufacturers make both. The affected products vary by manufacturer and schedule. Confirm the exact maker, strength, and package with a pharmacist before switching.

This dated snapshot records one NDC/package entry per row. Check ASHP’s primary bulletin for any later update and ask your pharmacist about current dispensing inventory.

Of the 17 affected NDC/package entries, 6 are once-weekly and 11 are twice-weekly. Of the 29 available entries,12 are once-weekly and 17 are twice-weekly.

The August 12 ASHP bulletin lists 29 available NDC/package entries:12 once-weekly and 17 twice-weekly. Source-listed availability is not a promise that a pharmacy has stock. Confirm the exact manufacturer, schedule, strength, and package identifier with the pharmacist.

FDA and ASHP use different inclusion and resolution rules. FDA evaluates national supply, while ASHP confirms qualifying disruptions with manufacturers after reports from healthcare professionals and others. ASHP can list a disruption when some presentations remain available. A missing Current FDA record is not a guarantee that a particular prescription is easy to fill.

FDA’s September 3, 2026 supply statement acknowledges patch-access difficulties, reports that supply nearly doubled over the previous year, and describes work with manufacturers to expand output. The statement does not announce a universal restock date. Check with your pharmacist and prescriber about an appropriate available product before changing treatment.

The demand signal is unambiguous, and it comes from real-world dispensing data, not a survey.Truveta reported that estrogen patch dispensing more than tripled — from 6.2 to 19.9 per 1,000 women between 2018 and February 2026 — making the patch the single most common form of estrogen therapy by early 2026. Prescribing among women aged 45–54 rose 184.2% over the same window, reaching roughly 1 in 20 women in that group.

Supply, meanwhile, is structurally slow to respond. Only about six manufacturers make estradiol patches for the U.S. market, and transdermal patches are, in Sandoz’s own words to CNBC, “highly complex” to manufacture. ASHP’s Michael Ganio has explained that generic makers often run a product on a shared production line for part of the year and then switch that line to something else — so adding output can mean waiting for the next cycle, a harder call for generics because they carry lower margins than brand-name drugs.

But we won’t let the demand story quietly become a causation claim. The bulletin is careful about whyeach product is short, and so are we. Here is exactly what the sources establish — and where the explanation runs out.

There’s also an honest wrinkle we won’t paper over: Truveta explicitly reported that it did notsee patch dispensing decline despite the shortage reports, and that no FDA shortage announcement had been made during its study period. The likely explanation is timing — patches are often dispensed in 30- or 90-day supplies, and patients switch brands or pharmacies to get filled — so a real disruption can take months to show up in dispensing data.

There is no single national end date, and the resupply picture varies sharply by manufacturer.ASHP’s bulletin gives no release estimate for the affected Amneal products, describes Noven’s supply as intermittent with weekly releases, and describes Zydus as rationing to existing customers — three different situations under one “shortage” headline. Here is what each affected manufacturer reported.

ASHP assigns no single nationwide end date. Its August 12 bulletin, checked October 3, reports different supply notes by affected manufacturer; none predicts when a particular pharmacy will refill a prescription. Confirm local inventory with the pharmacist and discuss any treatment change with the prescriber.

This shortage is a supply-side hangover from a genuine shift in how menopause is treated.For two decades, hormone-therapy use sat well below its earlier peak after a 2002 Women’s Health Initiative study prompted strong safety warnings. In late 2025 the labeling changed, and demand responded fast. Here is the dated sequence.

We’re placing this context after the data on purpose, and framing it carefully: demand rose sharply, a small group of manufacturers couldn’t add complex patch capacity fast enough, and the strain landed hardest on twice-weekly products. Whether the labeling change causedany specific product shortage is a broader claim than any single source establishes — which is why the cause ledger above sticks to what’s provable.

We’d rather tell you where this data stops than let you over-read it. A few honest limits:

• National status is not local inventory. A product listed as available may be out of stock at your pharmacy today, and vice versa. We do not track individual pharmacy shelves.
• For practical steps for filling or transferring your existing prescription, our access guide explains what to confirm with a licensed pharmacy; this tracker does not check local inventory.
• Sources lag reality.ASHP updates as reports come in; the FDA’s data depends on manufacturer reporting; Truveta’s dispensing data can trail real supply changes by weeks because of 30- and 90-day fills. A snapshot is a snapshot, which is why we date everything.
• “Not on the FDA list” is not “no problem.” The two systems use different thresholds and different public formats.
• We don’t tell you what to take.This page reports supply status. It does not recommend switching products, and it is not a substitute for your prescriber or pharmacist, who can advise on FDA-approved alternatives — estradiol also comes as gels, sprays, oral tablets, and vaginal forms (see our FDA-Approved HRT Reference for a full category breakdown) — as well as dose equivalence and whether a brief gap is acceptable. Compounded estradiol is a separate category that is not FDA-approved, and quality can vary; that’s a conversation for a clinician, not a default.